Steven M. Paul

Steven M. Paul is an American neuroscientist and pharmaceutical executive.

Not to be confused with Steve Paul and Steven Paul. For the alternative spelling see Stephen Paul (disambiguation).

Career

In 1982, Paul and his colleague, Phil Skolnick, published their discovery that the ethyl ester of beta carboline-3-carboxylic acid (beta-CCE) triggered anxiety in people; the work was recognized as an example of the growing ability of neuroscientists to understand the biochemistry of emotions.[1] In 1989, he was the senior scientist on a paper published in Nature that undercut the claim that mutations in a gene on chromosome 11 caused bipolar disorder, which previously had been hailed as evidence that studies of genetics would lead to definitive biomarkers for mental illnesses.[2] Around this time, he became the scientific director of intramural research at NIMH.[3]

Paul moved to Eli Lilly and Company in 1993 as vice president for central nervous system discovery research and decision-phase medical research.[3] He was described by a New York Times reporter in 1996 as being "one of those at the forefront of the development of the coming breed of psychiatric medications."[3] In 1998 he was named group vice president, therapeutic area discovery research and clinical investigation, and by 2003 he was Lilly's executive vice president for science and technology and president of Lilly Research Laboratories.[4] He helped organize cooperation and funding from pharmaceutical companies in establishing the Alzheimer's Disease Neuroimaging Initiative, a non-proprietary collaborative research effort to establish imaging biomarkers for Alzheimer's disease.[5]

In the early 2000s, Paul helped lead the company toward a new model of drug discovery and development that focused on getting proof of concept as early as possible in the research process, in order to avoid failures in Phase II clinical trials.[6][7] As part of that effort he helped establish Lilly Chorus, an autonomous business unit that was created to design and execute studies that would allow drug candidates to "fail early" instead of lingering in a company's pipeline.[8][9][10][11] He also led Lilly's work on Alzheimer's drugs, which however dramatically failed in Phase III clinical trials.[12][13]


Boards and memberships

Paul is a member of the National Academy of Sciences and the National Institute of Medicine.[14]

As of 2017 he was on the board of directors for Butler University, the Foundation for the National Institutes of Health, and the Eli Lilly & Co. Foundation.[14] As of 2017 he was also on the board of directors of Alnylam, SAGE Therapeutics, Tal Medical, Sigma-Aldrich, Karuna Therapeutics, Voyager Therapeutics, Constellation Pharmaceuticals, Seaside Therapeutics, the Biotechnology Industry Organization, and DemeRx.[14]

References
  1. Schmeck, Jr, Harold M. (7 September 1982). "The Biology of Fear and Anxiety: Evidence Points to Chemical Triggers". The New York Times.
  2. Jr, Harold M. Schmeck (7 November 1989). "Scientists Now Doubt They Found Faulty Gene Linked to Mental Illness". The New York Times.
  3. Goleman, Daniel (19 November 1996). "Research on Brain Leads to Pursuit Of Designer Drugs". The New York Times.
  4. Harris, Gardiner (22 November 2003). "Cialis, Lilly's Entry in Impotence Market, Is Approved". The New York Times.
  5. Kolata, Gina (12 August 2010). "Rare Sharing of Data Led to Results on Alzheimer's". The New York Times.
  6. Berenson, Alex (3 July 2005). "Blockbuster Drugs Are So Last Century". The New York Times.
  7. Paul, SM; Mytelka, DS; Dunwiddie, CT; Persinger, CC; Munos, BH; Lindborg, SR; Schacht, AL (March 2010). "How to improve R&D productivity: the pharmaceutical industry's grand challenge". Nature Reviews. Drug Discovery. 9 (3): 203–14. doi:10.1038/nrd3078. PMID 20168317.
  8. Bonabeau, E; Bodick, N; Armstrong, RW (March 2008). "A more rational approach to new-product development". Harvard Business Review. 86 (3): 96–102, 134. PMID 18411967.
  9. Paul, S. (January 2009). "An Audience with: Steven Paul". Nature Reviews. Drug Discovery. 8 (1): 14. doi:10.1038/nrd2800. PMID 19116623.
  10. Henderson, Rebecca; Reavis, Cate (March 13, 2008). "Eli Lilly: Recreating Drug Discovery for the 21st Century" (PDF). MIT Sloan School of Management.
  11. Owens, PK; Raddad, E; Miller, JW; Stille, JR; Olovich, KG; Smith, NV; Jones, RS; Scherer, JC (January 2015). "A decade of innovation in pharmaceutical R&D: the Chorus model". Nature Reviews. Drug Discovery. 14 (1): 17–28. doi:10.1038/nrd4497. PMID 25503514.
  12. Wall, J.K. (August 11, 2012). "Alzheimer's quest puts Lilly to test". Indiana Business Journal.
  13. Taylor, Phil (November 23, 2016). "Alzheimer's hopes dashed as Lilly gives up on amyloid drug solanezumab". FierceBiotech.
  14. "Paul profile as Alnyam Board Member". Wall Street Journal. Retrieved 1 March 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.